Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $2.38B |
| Net Income (Most Recent Fiscal Year) | $770.95M |
| PE Ratio (Current Year Earnings Estimate) | 10.60 |
| PE Ratio (Trailing 12 Months) | 10.56 |
| PEG Ratio (Long Term Growth Estimate) | 1.47 |
| Price to Sales Ratio (Trailing 12 Months) | 12.63 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.21 |
| Pre-Tax Margin (Trailing 12 Months) | 55.63% |
| Net Margin (Trailing 12 Months) | 33.88% |
| Return on Equity (Trailing 12 Months) | 29.25% |
| Return on Assets (Trailing 12 Months) | 14.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.66 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.66 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.86 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.30 |
| Earnings per Share (Most Recent Fiscal Year) | $4.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 575.83M |
| Free Float | 467.35M |
| Market Capitalization | $30.84B |
| Average Volume (Last 20 Days) | 3.69M |
| Beta (Past 60 Months) | 0.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.84% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.35% |
| Annual Dividend (Based on Last Quarter) | $0.94 |
| Dividend Yield (Based on Last Quarter) | 1.76% |